{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:57:40Z","timestamp":1771009060041,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T00:00:00Z","timestamp":1237939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>We conducted a phase\u00a0I\/II study to investigate the toxicity, pharmacokinetics, and efficacy profiles of cladribine with 2\u2010h intravenous infusion for five consecutive days every four weeks in Japanese patients with relapsed indolent B\u2010cell lymphoma. This was a dose\u2010escalation study to confirm the safety of the doses which have been recommended for Caucasian patients (phase\u00a0I), and to further evaluate the efficacy and safety (phase\u00a0II). In the phase\u00a0I portion for nine patients, no dose\u2010limiting toxicities were observed at levels\u00a01 (0.09\u00a0mg\/kg\/day, <jats:italic>n<\/jats:italic>\u00a0=\u00a03) and 2 (0.12\u00a0mg\/kg\/day, <jats:italic>n<\/jats:italic>\u00a0=\u00a06). No appreciable accumulation of plasma cladribine concentration was suggested. We enrolled a total of 20\u00a0patients, and an additional 14\u00a0patients in the phase\u00a0II portion at level\u00a02 (0.12\u00a0mg\/kg\/day). Eighteen patients, including 13 with follicular lymphoma, were eligible for efficacy evaluation, and 15 (83%) were pretreated with rituximab. The overall response rate was 50% (9\/18; 80% confidence interval, 35\u201365%), with 11% (2\/18) complete response. With a median follow\u2010up of 296\u00a0days, the estimated median time to progression for 18 eligible patients was 382\u00a0days. The most frequent adverse events were hematologic toxicities, including grade\u00a04 neutropenia. Non\u2010hematologic toxicities were mild. In conclusion, cladribine with 2\u2010h intravenous infusion for five consecutive days every four weeks is effective with acceptable toxicities for Japanese patients with relapsed indolent B\u2010cell lymphoma, including those pretreated with rituximab. (<jats:italic>Cancer Sci<\/jats:italic> 2009; 100: 1344\u20131350)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01162.x","type":"journal-article","created":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T10:07:06Z","timestamp":1237975626000},"page":"1344-1350","source":"Crossref","is-referenced-by-count":7,"title":["Phase\u00a0I\/II and pharmacokinetic study of cladribine with 2\u2010h infusion in Japanese patients with relapsed indolent B\u2010cell lymphoma mostly pretreated with rituximab"],"prefix":"10.1111","volume":"100","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Nawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Matsusako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.7.2.289"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/jco.2008.26.15_suppl.8616","article-title":"Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R\u2010CHOP) in untreated indolent B\u2010NHL: 7\u2010year follow\u2010up results","volume":"26","author":"Itoh K","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92826-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004193221605"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.6.1918"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.983"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4828"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.3.371"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","article-title":"2\u2010Chlorodeoxyadenosine is an active salvage therapy in advanced non\u2010Hodgkin's lymphoma","volume":"12","author":"Hoffman M","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04050"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23558"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.4.535"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/27.3.146"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04077"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04128"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02986621"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.4.737.737"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709109163"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199709114170","article-title":"Intermittent infusion of cladribine (CdA) in previously treated patients with low\u2010grade non\u2010Hodgkin's lymphoma","volume":"25","author":"Liliemark J","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2370::AID-CNCR17>3.0.CO;2-M"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909145712"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00140-3"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00143-0"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909167397"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819032000159825"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087251"},{"key":"e_1_2_6_33_2","first-page":"385","article-title":"Cellular pharmacokinetics of 2\u2010chloro\u20102\u2032\u2010deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients","volume":"1","author":"Liliemark J","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008325110921"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.978"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01162.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01162.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:11:39Z","timestamp":1697184699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01162.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01162.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01162.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}